Status:

COMPLETED

Efficacy and Safety Comparison of Metformin/Glimepiride Combination Versus Each Compound Alone in New Diagnosed Type 2 Diabetes Patients

Lead Sponsor:

Sanofi

Conditions:

Diabetes Mellitus, Type 2

Eligibility:

All Genders

18-78 years

Phase:

PHASE3

Brief Summary

Primary Objective: \- To demonstrate the superiority of glimepiride and metformin free combination in comparison to glimepiride or metformin alone in terms of Hb1Ac reduction during a 24-week treatme...

Detailed Description

The study duration for each patient is approximately 27 weeks with 3 periods: 2-week screening period followed by 24-week treatment period where patient is assigned to one of the three arms according ...

Eligibility Criteria

Inclusion

  • Inclusion criteria
  • Patients with type 2 diabetes mellitus, as defined by the World Health Organization (WHO), diagnosed within one year prior to the screening visit
  • Signed informed consent, obtained prior to any study procedure
  • Exclusion criteria
  • Age \< 18 and =\> 78 years old
  • HbA1c \< 7.6% or \> 9%
  • BMI \> 35 kg/m2
  • Diabetes other than type 2 diabetes (e.g.: type 1 diabetes, diabetes secondary to pancreatic disorders, drug or chemical agent intake...)
  • Subjects currently receiving or who have received any hypoglycemic agent within 3 months before screening visit
  • The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Exclusion

    Key Trial Info

    Start Date :

    February 1 2012

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    January 1 2014

    Estimated Enrollment :

    538 Patients enrolled

    Trial Details

    Trial ID

    NCT01459809

    Start Date

    February 1 2012

    End Date

    January 1 2014

    Last Update

    January 21 2015

    Active Locations (55)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 14 (55 locations)

    1

    Investigational Site Number 01206

    Algeries, Algeria

    2

    Investigational Site Number 01203

    Oran, Algeria, 31000

    3

    Investigational Site Number 01205

    Sétif, Algeria, 19000

    4

    Investigational Site Number 17003

    El Espinal, Colombia

    Efficacy and Safety Comparison of Metformin/Glimepiride Combination Versus Each Compound Alone in New Diagnosed Type 2 Diabetes Patients | DecenTrialz